Head and Neck Cancers

Latest News

head and neck cancer
Pembrolizumab With or Without Chemotherapy Continues to Show Survival Benefit Over Cetuximab Plus Chemotherapy in Recurrent/Metastatic HNSCC

February 7th 2023

Patients with head and neck squamous cell carcinoma continued to displayed a survival benefit with pembrolizumab at a 4-year follow-up.

Adding Docetaxel to Radiation Boosts Survival in Cisplatin-Ineligible HNSCC

February 6th 2023

Recurrent/Metastatic HNSCC
Checkmate 651 Misses Primary End Points With Frontline Nivolumab/Ipilimumab in Recurrent/Metastatic HNSCC

January 19th 2023

head and neck cancer
Low-Dose Nivolumab Plus Chemotherapy an Accessible Alternative to Full-Dose Checkpoint Inhibitors in Head and Neck Cancer

January 10th 2023

Smiling Patient
Black Mulberry Extract Shows Efficacy in Oral Mucositis Management for Patients Receiving Chemotherapy

December 22nd 2022

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.